Mode
Text Size
Log in / Sign up
N/A N=360 Randomized Single-blind Treatment

Ideas Moving Parents and Adolescents to Change Together (IMPACT)

Overweight · Obese

Enrolled (actual)
360
Serious AEs
24.2%
Results posted
Aug 2020
Primary outcome: Primary: Slope of Body Mass Index (BMI) — 0.821; 1.083; 0.952 kg/m^2/year

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
HealthyCHANGE (Behavioral); SystemCHANGE (Behavioral)
Age
Pediatric · 11+ yrs
Sex
All
Sponsor
Case Western Reserve University
Primary completion
Jan 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Slope of Body Mass Index (BMI)
0.821; 1.083; 0.952
SECONDARY
Dietary Intake- Calories Per Day
12.49; 6.99; 24.03
SECONDARY
Blood Pressure
1.245; 1.130; 0.886; -0.136; -0.074; -0.162
SECONDARY
Physical Activity
-3.370; -4.619; -3.523; 10.501; 13.052; 11.022
SECONDARY
Sleep
-1.061; -1.552; -1.184; -0.239; -0.361; -0.273
SECONDARY
Cardiometabolic Factors- Fasting Glucose, HDL Cholesterol, LDL Cholesterol, Total Cholesterol
-0.146; -0.520; -0490; -0.300; -0.600; -0.385
SECONDARY
Body Composition- BMI Percentile
-1.375; -0.258; -1.082
SECONDARY
Fitness
1.084; 0.533; 1.715
SECONDARY
Quality of Life- Perceived Stress
0.313; -0.049; -0.026
SECONDARY
Dietary Intake- Percent Calories From Fat
0.139; -0.050; -0.055
SECONDARY
Dietary Intake- Fruit and Vegetable Servings
-0.061; -0.050; -0.055; 0.013; 0.008; -0.008
SECONDARY
Dietary Intake- Sodium
-0.42; 26.46; 39.15
SECONDARY
Cardiometabolic Factors- Hemoglobin A1c
-0.040; -0.021; -0.017
SECONDARY
Cardiometabolic Factors- High-sensitivity C-reactive Protein
-0.013; -0.002; -0.0185
SECONDARY
Cardiometabolic Factors- Insulin
0.772; 0.406; 0.228
SECONDARY
Cardiometabolic Factors- HOMA-IR
0.032; 0.037; 0.004
SECONDARY
Body Composition- Waist-to-height Ratio
-0.003; 0.002; -0.001
SECONDARY
Body Composition- Waist Circumference
1.814; 2.339; 2.200
SECONDARY
Body Composition- Percent Body Fat
-0.246; 0.299; -0.044

Summary

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institute of Health (NIH) has sponsored a consortium of four sites across the United States, entitled Childhood Obesity Prevention and Treatment Research (COPTR). Each site has its own protocol. Case Western Reserve/Cleveland's project is entitled "Targeting Obesity and Blood Pressure in Urban Youth". The site name is IMPACT (Ideas Moving Parents and Adolescents to Change Together). The project assesses the effects of three interventions on Body Mass Index(BMI) in overweight and obese urban 5th-8th grade youth: a cognitive-behavioral intervention (HealthyChange), a systems improvement intervention (SystemsChange), and an education-only intervention (Tools4Change). In addition the study assesses the potential additional impact of a school-community based intervention on outcomes. The project has two phases: a formative phase (including focus groups and a pilot) and the main trial. The main trial will take place over approximately four years.

Eligibility Criteria

Inclusion Criteria

  • Students entering the 6th grade who are found at the standard school screenings to be overweight or obese
  • (BMI 85th- 94th percentile or > 95th percentile for age/sex respectively)

Exclusion Criteria

  • Taking medications that alter appetite or weight (e.g. glucocorticoids, metformin, insulin, Risperidone (Risperdal), Olanzapine (Zyprexa), Clozapine(Clozaril), Quetiapine (Seroquel), Ziprasidone (Geodon), Carbamazepine (Tegretol), Valproic acid (Depakote/Depakene/Depacon), Aripiprazole (Abilify), Orlistat (Xenical), Sibutramine (Meridia), Phentermine, Diethylproprion (Tenuate), Topirimate (Topamax), glitazones (thiazolidinediones)
  • Inability to understand English
  • Stage 2 hypertension or stage 1 hypertension with end organ damage (left ventricular hypertrophy, microalbuminuria)
  • Severe behavioral problems that preclude group participation (as reported by parent/guardian)
  • Child involvement in another weight management program
  • Family expectation to move from the region within 1 year
  • The presence of a known medical condition that itself causes obesity (e.g., Prader-Willi syndrome) or interfere with HbA1C ( sickle cell disease)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01514279). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search